FDA Warns Fresenius Over Leaking Sterile Dialysis Bags and cGMP Failures at Ogden Plant
核心洞察
The FDA issued a warning letter to Fresenius Medical Care North America's Ogden, Utah facility on August 25, 2026, citing significant cGMP violations under 21 CFR Parts 210 and 211.
The most serious finding involved leaking Delflex Peritoneal Dialysis Solution (搜索) bags, with 35 complaints covering about 156 bags from multiple batches attributed to holes caused by printing.
Fresenius assigned the lowest severity level to the leaks despite its own risk matrix identifying peritonitis (搜索) as a potential harm, exposing patients to non-sterile products and potentially life-threatening complications.
The US FDA has issued a warning letter to Fresenius Medical Care North America over significant Current Good Manufacturing Practice (cGMP) violations at its drug manufacturing facility in Ogden, Utah, including recurring leaks in sterile peritoneal dialysis solution bags. The warning letter, dated August 25, 2026, was addressed to Fresenius USA Manufacturing, Inc., doing business as Fresenius Medical Care North America Ogden Plant, at 475 W. 13th St., Ogden, Utah (FEI 1713747).
The FDA inspected the facility from March 2 to 6, 2026, and determined that the plant's manufacturing methods, facilities, and controls did not conform with cGMP requirements for finished pharmaceuticals under 21 CFR Parts 210 and 211.
Leaking Delflex Peritoneal Dialysis Solution Bags
The regulator's most serious finding concerned the company's investigation of leaking bags of Delflex Peritoneal Dialysis Solution (搜索). Fresenius initiated an investigation in August 2025 after receiving a trend of complaints relating to leaking bags. The investigation ultimately identified 35 complaints involving about 156 bags from multiple batches, with the company attributing the leaks to holes caused by printing.
However, the FDA found that Fresenius assigned the lowest severity level to the issue, even though its own risk management matrix identified peritonitis (搜索) as a potential harm and recommended the highest severity level. The company did not initially recall the affected batches, although it subsequently initiated a recall in April 2026.
According to the FDA, this decision potentially exposed peritoneal dialysis patients to non-sterile drug products, which could increase the risk of peritonitis (搜索) and potentially serious or life-threatening complications. The agency also highlighted numerous complaints, Field Alert Reports, and recalls involving leaking large-volume parenteral (LVP) bags manufactured at the site during the previous three years, including two reports involving microbial contamination.
A Delayed Signal in a High-Risk Supply Chain
The warning letter represented a late signal in a chain that should have triggered corrective action much earlier. Customer complaints about Fresenius Ogden product quality were arriving before the FDA walked in the door in March 2026, and had grown numerous enough that the FDA specifically characterized them as a "complaint trend," not isolated incidents. A Form 483 followed the March inspection, documenting cGMP observations the facility was expected to address. The August 25 warning letter then formalized what the complaint data and the 483 had already suggested: the Ogden plant's quality management system had structural failures, not a single event.
The Ogden facility manufactures sterile injectables, including dialysis solutions packaged in flexible bags. A leaking bag means a compromised sterile barrier, which in a dialysis context translates to direct exposure risk for a population with no physiological margin for error.
FDA Demands Wider Corrective Action
The FDA has called for an independent assessment of the root causes of the leaks, including Fresenius' printing technology, equipment, and personnel handling. The agency has also requested assessments of alternative printing technologies, leak-detection methods, equipment qualification, process capability, and statistical process control.
The agency separately found deficiencies in Fresenius' visual inspection programme for sterile injectable products, including inadequate qualification of inspection personnel and insufficiently representative particulate challenge kits.
Related Recall and Broader Quality Concerns
The FDA warning comes shortly after Fresenius Kabi recalled one lot of its Tyenne (tocilizumab-aazg (搜索)) injection in the US. On August 10, the company said an internal investigation had identified glass particles in 400 mg/20 mL vials, prompting a nationwide recall. The company warned that injectable glass particles can cause local irritation and, in serious cases, vascular blockage, pulmonary embolism, organ damage, or death.
While the two events concern different Fresenius businesses and products, the close timing to the new FDA warning letter could prompt customers to look more closely at the Group's wider manufacturing and quality-control systems.
Implications for Sponsor Oversight
Fresenius Kabi's contract manufacturing operation services pharmaceutical and biotech partners across both commercial supply and clinical trial drug manufacture. If any portion of the products leaving the Ogden facility feed active investigational drug programs, the sponsor oversight implications are significant. The FDA's guidance on contract manufacturing arrangements states that quality agreements between drug owners and contract facilities must cover audits, inspections, and communication of findings, and "should allow owners to evaluate" the facility's compliance posture.
The compliance gap between what quality agreements specify and what contract manufacturing organization (CMO) quality systems actually deliver is widest at the trend-detection layer. Individual deviations get caught, but diffuse, cross-batch, cross-customer signals — the kind that show up as a complaint trend rather than a single critical failure — persist longer because no single system owns them cleanly.
Regulatory Outlook
The FDA has requested a written response within 15 working days and warned that failure to adequately address the violations could result in further regulatory or legal action, including seizure or injunction. The next signal to watch is Fresenius Ogden's formal response to the August 25 warning letter, which will either demonstrate a corrective and preventive action (CAPA) program substantial enough to close the FDA's observations or trigger the next escalation: import alert, consent decree proceedings, or facility suspension.